Results 21 to 30 of about 38,655 (210)

A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report

open access: yesSAGE Open Medical Case Reports, 2023
Bullous pemphigoid is an acquired autoimmune subepidermal blistering disease that can arise following exposure to systemic medication, referred to as drug-induced bullous pemphigoid.
Louise M Gresham, Mark G Kirchhof
doaj   +1 more source

AUTOIMMUNE BULLOUS DERMATOSES. DIFFERENTIAL DIAGNOSIS

open access: yesVestnik Dermatologii i Venerologii, 2017
The review presents modern ideas concerning autoimmune bullous dermatoses (pemphigoid group): Duhring disease, bullous pemphigoid, cicatrizing pemphigus, pemphigoid gestationis, linear IgA bullous dermatosis and acquired bullous epidermolysis ...
V. I. Al'banova, M. A. Nefedova
doaj   +1 more source

Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England

open access: yesBMJ Open, 2020
Objectives The validity of bullous pemphigoid and pemphigus vulgaris recording in routinely collected healthcare data in the UK is unknown. We assessed the positive predictive value (PPV) for bullous pemphigoid and pemphigus vulgaris primary care Read ...
Yana Vinogradova   +6 more
doaj   +1 more source

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature

open access: yesFrontiers in Medicine, 2018
An 83-year-old patient developed erosions and a blister of the gingival mucous membrane, 6 months after discontinuation of the anti-programmed death-1 (anti PD-1) pembrolizumab therapy administered for 10 months for a metastatic melanoma.
C. Zumelzu   +10 more
semanticscholar   +1 more source

Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.

open access: yesJAMA dermatology, 2022
Importance Bullous pemphigoid is a difficult-to-treat autoimmune blistering skin disease that predominantly affects older adults and is associated with an increased mortality rate. Objective To examine the safety and therapeutic potential of nomacopan,
C. Sadik   +12 more
semanticscholar   +1 more source

Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2013
Bullous pemphigoid is an autoimmune subepidermal blistering dermatosis that is uncommon in childhood. We report a case of a female infant, 3 months old, which presented clinical and laboratory data for the confirmatory diagnosis of bullous pemphigoid ...
Eugenio Galdino de Mendonça Reis-Filho   +3 more
doaj   +1 more source

The Intriguing Links between Psoriasis and Bullous Pemphigoid

open access: yesJournal of Clinical Medicine, 2022
The coexistence of psoriasis with autoimmune bullous diseases (AIBDs), particularly bullous pemphigoid (BP), has been documented in case reports and series, as well as in epidemiological studies. The onset of psoriasis precedes that of BP in the majority
C. Maronese   +5 more
semanticscholar   +1 more source

The global incidence of bullous pemphigoid: a systematic review and meta‐analysis

open access: yesBritish Journal of Dermatology, 2021
Bullous pemphigoid (BP) is an autoimmune blistering disorder that mainly affects older people. Although the disease is associated with considerable morbidity and mortality, the burden of disease worldwide is unclear.
Matty Persson   +5 more
semanticscholar   +1 more source

Increased Risk of Squamous Cell Carcinoma of the Skin and Lymphoma Among 5,739 Patients with Bullous Pemphigoid: A Swedish Nationwide Cohort Study

open access: yesActa Dermato-Venereologica, 2020
Evidence about the association of bullous pemphigoid and the risk of cancer is conflicting. Patients diagnosed with bullous pemphigoid (n = 5,739) between 2005 and 2016 were matched with a control cohort from the general population (n = 17,168) to ...
Zeyad Albadri   +4 more
doaj   +1 more source

Evaluating risk of bullous pemphigoid after mRNA COVID‐19 vaccination

open access: yesBritish Journal of Dermatology, 2022
Our results suggest mRNA COVID-19 vaccination is not associated with increased risk of new-onset bullous pemphigoid. Hopefully, health care professionals may use the findings reported herein to counsel patients experiencing vaccine hesitancy for concerns
Morgan Birabaharan   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy